Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Zometa reduces bone loss in patients receiving breast cancer treatment
June 16th, 2005
Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence). Importantly, several studies have shown that women treated with hormonal therapy in the adjuvant breast cancer setting are at risk of bone loss. This new data from the Zometa-Femara Adjuvant Synergy Trial (Z-FAST) study offers evidence that Zometa may prevent bone loss in these patients. The final data demonstrate a...
Source: Women's Health Weekly (2005-06-16)
|
